# Avanzanite Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avanzanite-bioscience-b-v

- Industry: Pharmaceuticals
- Headquarters: Amsterdam, Netherlands
- Website: www.avanzanite.com/
- Total disclosed funding: $37M
- Latest round: Series A (Nov 18, 2025)
- Investors on record: 1

## About

Avanzanite Bioscience B.V., based in the Netherlands, is dedicated to the commercialization of orphan medicines, enhancing access to treatments for rare diseases throughout Europe. 

Founded in 2021 by co-founders Adam Plich, and Anant Murthy and based in Amsterdam, Netherlands, Avanzanite Bioscience B.V. specializes in the distribution of orphan medicines. In November 2025, Avanzanite Bioscience B.V. raised EUR 32 million in series A funding from investor MVM Partners.

Avanzanite Bioscience B.V. specializes in the commercialization and distribution of orphan medicines, focusing on improving patient access to treatments for rare diseases across Europe. The company’s core offerings include exclusive distribution agreements for various medicinal products, notably SIBNAYAL for distal Renal Tubular Acidosis, AKANTIOR for Acanthamoeba Keratitis, and PYRUKYND for adults with Pyruvate Kinase Deficiency. These products address severe medical needs and enhance patient outcomes by providing innovative therapies previously unavailable in certain regions. Avanzanite serves a diverse clientele, including emerging biopharmaceutical companies looking to penetrate European markets without establishing extensive local infrastructure, operating across multiple European countries such as Germany, Austria, Switzerland, Greece, and Ireland.

Avanzanite Bioscience's revenue model is primarily structured around exclusive licensing and distribution agreements with biopharmaceutical originators. These partnerships facilitate the commercialization of late-stage or European Commission-approved medicines, enabling Avanzanite to act as a singular distributor for its partners across non-core territories. The company’s flagship products, including SIBNAYAL, AKANTIOR, and PYRUKYND, are marketed through established distribution networks, allowing for efficient market access and regulatory compliance. Transaction structures typically feature partnerships where fees are based on product sales, with Avanzanite receiving a share of revenue from the distribution of these therapies, maximizing value for both Avanzanite and its partners while ensuring patients have access to critical treatments.

The company will use the November 2025 funding to expand its rare disease medicine portfolio and strengthen European market access.

## Funding rounds

- Series A, Nov 18, 2025, $37M — MVM Partners

## Investors

- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series A